Home Prostate / Prostate Cancer BRIEF-Ipsen Joins Clinical Collaboration To Evaluate Lung And Prostate Cancer Treatments

BRIEF-Ipsen Joins Clinical Collaboration To Evaluate Lung And Prostate Cancer Treatments

58
0

July 2 (Reuters) – IPSEN SA:

* IPSEN JOINS CLINICAL COLLABORATION TO EVALUATE CABOZANTINIB (CABOMETYX®) PLUS ATEZOLIZUMAB IN METASTATIC NON-SMALL CELL LUNG CANCER AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

* CLINICAL COLLABORATION MARKS AN IMPORTANT MILESTONE IN PARTNERSHIP WITH EXELIXIS TO FURTHER DEVELOP CABOZANTINIB

* PARTICIPATION WILL PROVIDE IPSEN ACCESS TO RESPECTIVE STUDY RESULTS TO SUPPORT POTENTIAL FUTURE REGULATORY SUBMISSIONS IN ITS TERRITORIES

* HAS AN EXCLUSIVE COLLABORATION AGREEMENT WITH EXELIXIS FOR FURTHER DEVELOPMENT AND COMMERCIALIZATION OF CABOZANTINIB OUTSIDE OF UNITED STATES AND JAPAN Source text for Eikon: Further company coverage: (Gdansk Newsroom)

https://www.reuters.com/article/brief-ipsen-joins-clinical-collaboration/brief-ipsen-joins-clinical-collaboration-to-evaluate-lung-and-prostate-cancer-treatments-idUSASN0008V5

This site uses Akismet to reduce spam. Learn how your comment data is processed.